Article
Biochemistry & Molecular Biology
Cristian Petrescu, Ioana R. R. Papacocea, Crisanda Vilciu, Oana A. A. Mihalache, Diana M. M. Vlad, Gabriela Marian, Brindusa E. E. Focseneanu, Cristian T. T. Sima, Constantin A. A. Ciobanu, Sorin Riga, Adela M. M. Ciobanu
Summary: This study aims to compare the profile of neurological soft signs in patients with predominantly negative symptoms of schizophrenia with patients who do not present a predominance of negative symptoms, as well as to assess the impact of treatment on the neurological function of these patients.
Review
Biochemistry & Molecular Biology
Claudio Brasso, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari, Paola Rocca
Summary: Schizophrenia is a highly disabling disease and negative symptoms have a negative impact on its outcome. Serotonin-dopamine activity modulators (SDAMs) such as aripiprazole, cariprazine, brexpiprazole, and lumateperone, show promise in reducing negative symptoms. This study reviewed existing evidence and highlights the need for further research on treatment strategies for negative symptoms in schizophrenia.
Article
Psychiatry
Milica M. Borovcanin, Slavica Minic Janicijevic, Natasa R. Mijailovic, Ivan P. Jovanovic, Nebojsa N. Arsenijevic, Katarina Vesic
Summary: This study suggests a potential association between uric acid levels and inflammatory responses in different phases of schizophrenia. However, the exact mechanism underlying the involvement of uric acid in the pathogenesis of schizophrenia remains uncertain.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Psychiatry
Alex S. Cohen, Elana Schwartz, Thanh P. Le, Tovah Cowan, Brian Kirkpatrick, Ian M. Raugh, Gregory P. Strauss
Summary: Negative symptoms in schizophrenia are critical but poorly understood, and while clinician ratings and biobehavioral data are both used for assessment, they are only moderately related due to differences in resolution. Resolving this discrepancy is crucial for better understanding and treating negative symptoms.
SCHIZOPHRENIA BULLETIN
(2021)
Article
Clinical Neurology
Cecilie Marie Nielsen, Pernille Kolbaek, David Dines, Martin Locht Pedersen, Andreas Aalkjaer Danielsen, Camilla Holmgard, Sanne Wissing, Anne-Mette Esbol, Nina Friis Bak Fuglsang, Tuan Dang Nguyen, Ole Mors, Mark Opler, Christoph U. Correll, Soren Dinesen Ostergaard
Summary: This study confirmed the validity of PANSS-6 ratings derived from SNAPSI in assessing the severity of schizophrenia symptoms among outpatients. These ratings were found to be acceptable and can be used as a tool for evaluating the severity of the disease.
JOURNAL OF PSYCHOPHARMACOLOGY
(2022)
Article
Psychiatry
Yaoyao Sun, Yuyanan Zhang, Zhe Lu, Hao Yan, Liangkun Guo, Yundan Liao, Tianlan Lu, Lifang Wang, Jun Li, Wenqiang Li, Yongfeng Yang, Hao Yu, Luxian Lv, Dai Zhang, Wenjian Bi, Weihua Yue
Summary: This study aimed to evaluate the changes in schizophrenia symptoms under different antipsychotic treatments by analyzing data from a multicenter clinical trial. The results identified central and bridge symptoms in the networks that changed over time. Acute antipsychotic treatment altered the network structure, and responsive patients showed lower global strength after treatment compared to resistant patients. The central and bridge symptoms remained prominent across different antipsychotics.
SCHIZOPHRENIA BULLETIN
(2023)
Article
Psychiatry
Miguel Castillo Sanchez, Mireia Fabregas Escurriola, Maria Isabel Fernandez Sanmartin, Iryna Solntseva, Daniel Berge Baquero, Alberto Goday Arno
Summary: A study conducted in Spain found that individuals with schizophrenia (SZ) or under treatment with antipsychotic drugs (TAD) have a higher risk of cardiovascular disease and cardiovascular mortality. The differences between SZ and TAD groups in terms of mortality and disease incidence indicate that the risk of cardiovascular disease in SZ may be independent of TAD.
PSYCHIATRY RESEARCH
(2021)
Article
Psychiatry
Silvana Galderisi
Summary: My research focuses on unmet needs in caring for people with schizophrenia, particularly negative symptoms which have a significant impact on the disease outcome and are not effectively addressed by existing treatments. In this commentary, I summarize the trajectory of my research, starting with my attempts to define the role of the dorsolateral prefrontal cortex in the pathogenesis of negative symptoms. I then discuss the importance of considering the heterogeneity and complexity of the construct in order to make progress in researching schizophrenia negative symptoms.
PSYCHIATRY RESEARCH
(2023)
Article
Clinical Neurology
Palmiero Monteleone, Giammarco Cascino, Alessio Maria Monteleone, Paola Rocca, Alessandro Rossi, Alessandro Bertolino, Eugenio Aguglia, Mario Amore, Enrico Collantoni, Giulio Corrivetti, Alessandro Cuomo, Antonello Bellomo, Enrico D'Ambrosio, Liliana Dell'Osso, Marianna Frascarelli, Giulia Maria Giordano, Luigi Giuliani, Carlo Marchesi, Cristiana Montemagni, Lucio Oldani, Federica Pinna, Maurizio Pompili, Rita Roncone, Rodolfo Rossi, Alberto Siracusano, Antonio Vita, Patrizia Zeppegno, Silvana Galderisi, Mario Maj
Summary: The study assessed the prevalence of EPS in schizophrenia patients treated with FGAs and SGAs, and found associations between EPS and the severity of the illness, neurocognitive impairments, and social cognition deficits. EPS were shown to impact patients' neurocognitive functions, but did not directly affect their social cognition abilities.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Review
Medicine, General & Internal
Mitchell D. Arnovitz, Andrew J. Spitzberg, Ashkhan J. Davani, Nehal P. Vadhan, Julie Holland, John M. Kane, Timothy Michaels
Summary: The negative symptoms of schizophrenia severely limit daily functioning, and there are currently no FDA-approved treatments for them. 3,4-Methylenedioxy methamphetamine (MDMA) has potential as a novel therapeutic due to its ability to enhance social interactions, generate empathy, and induce a state of metaplasticity in the brain. This review provides a rationale for the use of MDMA in the treatment of negative symptoms by reviewing the literature on negative symptoms, their treatment, MDMA, and MDMA-assisted therapy.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Psychiatry
Mats Bogren, Monica Soltesz, Stephan Hjorth
Summary: This case report describes a 45-year old man with schizoaffective disorder who had prodromal markers of the disorder since childhood. Over the years, he exhibited various symptoms of schizophrenia, with negative and affective symptoms being the earliest and most difficult to handle. The report highlights the successful use of cariprazine in alleviating the patient's negative and psychosocial issues, as an addition to his ongoing medication.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Neurosciences
Alba Toll, Laura Blanco-Hinojo, Daniel Berge, Xavier Duran, Irene Canosa, Teresa Legido, Federico Marmol, Victor Perez-Sola, Emilio Fernandez-Egea, Anna Mane
Summary: This study suggests that low baseline BDNF levels, smaller left amygdala relative volume, and score on the PANSS negative subscale are significant predictors of outcomes in first-episode psychosis. These findings could help tailor treatments for individuals with first-episode psychosis.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE
(2022)
Article
Psychiatry
S. Galderisi, S. Kaiser, I Bitter, M. Nordentoft, A. Mucci, M. Sabe, G. M. Giordano, M. O. Nielsen, L. B. Glenthoj, P. Pezzella, P. Falkai, S. Dollfus, W. Gaebel
Summary: The treatment of negative symptoms in schizophrenia remains a challenge, with growing evidence on the effects of biological and psychosocial interventions. The distinction between primary and secondary negative symptoms is crucial for treatment selection, yet limited evidence is available. Good clinical practice is recommended for addressing secondary negative symptoms.
EUROPEAN PSYCHIATRY
(2021)
Article
Psychiatry
Michael Davidson, Jay Saoud, Corinne Staner, Nadine Noel, Sandra Werner, Elisabeth Luthringer, David Walling, Mark Weiser, Philip D. Harvey, Gregory P. Strauss, Remy Luthringer
Summary: This placebo-controlled trial of roluperidone showed significant improvement in negative symptoms and everyday functioning in patients with schizophrenia, suggesting the potential of roluperidone as a treatment option for this patient population.
SCHIZOPHRENIA BULLETIN
(2022)
Article
Pharmacology & Pharmacy
Farhana Islam, Xiaoyu Men, Kazunari Yoshida, Clement C. Zai, Daniel J. Mueller
Summary: Pharmacogenetics research has shown that genetic factors influence the efficacy and tolerability of antipsychotic treatment, with the most robust findings related to associations between polymorphisms in CYP2D6 and exposure and response to specific antipsychotics. Product labels and guidelines have provided dosing recommendations based on CYP2D6 metabolizer phenotypes.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Psychology, Developmental
Sophia Lustig, Michael Kaess, Nina Schnyder, Chantal Michel, Romuald Brunner, Alexandra Tubiana, Jean-Pierre Kahn, Marco Sarchiapone, Christina W. Hoven, Shira Barzilay, Alan Apter, Judit Balazs, Julio Bobes, Pilar Alejandra Saiz, Doina Cozman, Padraig Cotter, Agnes Kereszteny, Tina Podlogar, Vita Postuvan, Airi Varnik, Franz Resch, Vladimir Carli, Danuta Wasserman
Summary: Early detection and intervention can help prevent mental disorders and risk behaviors among adolescents, but many of them do not seek help. School-based screenings are a promising approach to identify at-risk adolescents and encourage help-seeking behavior. However, this study found that the intervention called ProfScreen did not significantly improve the use of mental health services or reduce the at-risk state among participants compared to the control group.
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
(2023)
Article
Psychology, Clinical
Arsime Demjaha, Silvana Galderisi, Birthe Glenthoj, Celso Arango, Armida Mucci, Andrew Lawrence, Owen O'Daly, Matthew Kempton, Simone Ciufolini, Lone Baandrup, Bjorn H. Ebdrup, Roberto Rodriguez-Jimenez, Maria Diaz-Marsa, Covadonga Martinez Diaz-Caneja, Inge Winter van Rossum, Rene Kahn, Paola Dazzan, Philip McGuire
Summary: This study found that the orbitofrontal and temporal cortices play an important role in the pathogenesis of negative symptoms in schizophrenia. These findings were evident in generally untreated FEP patients and are unlikely to be related to effects of previous treatment or illness chronicity.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Psychology, Clinical
Nathalie E. Holz, Dorothea L. Floris, Alberto Llera, Pascal M. Aggensteiner, Seyed Mostafa Kia, Thomas Wolfers, Sarah Baumeister, Boris Boettinger, Jeffrey C. Glennon, Pieter J. Hoekstra, Andrea Dietrich, Melanie C. Saam, Ulrike M. E. Schulze, David J. Lythgoe, Steve C. R. Williams, Paramala Santosh, Mireia Rosa-Justicia, Nuria Bargallo, Josefina Castro-Fornieles, Celso Arango, Maria J. Penzol, Susanne Walitza, Andreas Meyer-Lindenberg, Marcel Zwiers, Barbara Franke, Jan Buitelaar, Jilly Naaijen, Daniel Brandeis, Christian Beckmann, Tobias Banaschewski, Andre F. Marquand
Summary: This study aimed to reveal the neurobiological characteristics of disruptive behavior disorders (DBD) by integrating individual deviation patterns from multiple imaging modalities. The results showed that DBD patients exhibited increased age-related deviations in the amygdala, suggesting a possible maturational delay. Furthermore, the study identified neural signatures associated with aggression, including the default mode network (DMN), striatum, and amygdala.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Psychiatry
Laura Ferraro, Diego Quattrone, Daniele La Barbera, Caterina La Cascia, Craig Morgan, James B. Kirkbride, Alastair G. Cardno, Pak Sham, Giada Tripoli, Lucia Sideli, Fabio Seminerio, Crocettarachele Sartorio, Andrei Szoke, Ilaria Tarricone, Miquel Bernardo, Victoria Rodriguez, Simona A. Stilo, Charlotte Gayer-Anderson, Lieuwe de Haan, Eva Velthorst, Hannah Jongsma, Rutten B. P. Bart, Alexander Richards, Celso Arango, Paulo Rossi Menezez, Antonio Lasalvia, Sarah Tosato, Andrea Tortelli, Cristina Marta Del Ben, Jean-Paul Selten, Peter B. Jones, Jim van Os, Marta Di Forti, Evangelos Vassos, Robin M. Murray
Summary: This study identified four distinct transdiagnostic clusters among first-episode psychosis patients based on their premorbid and cognitive abilities. The study also found differences in polygenic risk scores, patterns of cannabis use, and genetic predisposition to schizophrenia among these clusters.
SCHIZOPHRENIA BULLETIN
(2023)
Review
Biochemistry & Molecular Biology
Marco Solmi, Giovanni Croatto, Giada Piva, Stella Rosson, Paolo Fusar-Poli, Jose M. Rubio, Andre F. Carvalho, Eduard Vieta, Celso Arango, Nicole R. DeTore, Elizabeth S. Eberlin, Kim T. Mueser, Christoph U. Correll
Summary: Psychosocial interventions play an important role in schizophrenia and early psychosis. However, the literature on this topic is heterogeneous and contradictory. This umbrella review summarizes the findings from multiple meta-analyses comparing the effectiveness of different psychosocial interventions with standard treatment or other active interventions. The results suggest that early intervention services and cognitive behavioral therapy have significant effects on symptom reduction and functional improvement in early psychosis. For schizophrenia patients, cognitive behavioral therapy, psychoeducation, and any family interventions show positive effects on symptom reduction, relapse prevention, and functional improvement.
MOLECULAR PSYCHIATRY
(2023)
Article
Psychology, Clinical
Giuseppe D'Andrea, Jatin Lal, Sarah Tosato, Charlotte Gayer-Anderson, Hannah E. Jongsma, Simona A. Stilo, Els van der Ven, Diego Quattrone, Eva Velthorst, Domenico Berardi, Paulo Rossi Menezes, Celso Arango, Mara Parellada, Antonio Lasalvia, Caterina La Cascia, Laura Ferraro, Daniele La Barbera, Lucia Sideli, Julio Bobes, Miguel Bernardo, Julio Sanjuan, Jose Luis Santos, Manuel Arrojo, Cristina Marta Del-Ben, Giada Tripoli, Pierre-Michel Llorca, Lieuwe de Haan, Jean-Paul Selten, Andrea Tortelli, Andrei Szoke, Roberto Muratori, Bart P. Rutten, Jim van Os, Peter B. Jones, James B. Kirkbride, Robin M. Murray, Marta di Forti, Ilaria Tarricone, Craig Morgan
Summary: This study examined the prevalence of child maltreatment (CM) among migrants and found that migrants had a higher prevalence of CM. Migrant status attenuated the association between CM and first-episode psychosis (FEP). The higher exposure to CM among migrants accounted for a greater proportion of FEP cases.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Luis Alameda, Zhonghua Liu, Pak C. Sham, Monica Aas, Giulia Trotta, Victoria Rodriguez, Marta Di Forti, Simona A. Stilo, Radhika Kandaswamy, Celso Arango, Manuel Arrojo, Miguel Bernardo, Julio Bobes, Lieuwe de Haan, Cristina Marta Del-Ben, Charlotte Gayer-Anderson, Lucia Sideli, Peter B. Jones, Hannah E. Jongsma, James B. Kirkbride, Caterina La Cascia, Antonio Lasalvia, Sarah Tosato, Pierre-Michel Llorca, Paulo Rossi Menezes, Jim van Os, Diego Quattrone, Bart P. Rutten, Jose Luis Santos, Julio Sanjuan, Jean-Paul Selten, Andrei Szoke, Ilaria Tarricone, Andrea Tortelli, Eva Velthorst, Craig Morgan, Emma Dempster, Eilis Hannon, Joe Burrage, Daniella Dwir, Atheeshaan Arumuham, Jonathan Mill, Robin M. Murray, Chloe C. Y. Wong
Summary: Studies have found that DNA methylation is sensitive to childhood adversity in psychotic disorders, but it is unclear whether it mediates the association between childhood adversity and psychosis. This study found that childhood adversity was associated with psychosis, but no specific CpG sites were found to mediate the association. However, there were differentially methylated probes associated with genes previously linked to psychosis.
MOLECULAR PSYCHIATRY
(2023)
Article
Genetics & Heredity
Dongjing Liu, Dara Meyer, Brian Fennessy, Claudia Feng, Esther Cheng, Jessica Johnson, You Jeong Park, Marysia-Kolbe Rieder, Steven Ascolillo, Agathe de Pins, Amanda Dobbyn, Dannielle Lebovitch, Emily Moya, Tan-Hoang Nguyen, Lillian Wilkins, Arsalan Hassan, Henry Aghanwa, Katherine E. Burdick, Joseph D. Buxbaum, Enrico Domenici, Sophia Frangou, Annette M. Hartmann, Claudine Laurent-Levinson, Dheeraj Malhotra, Carlos N. Pato, Michele T. Pato, Kerry Ressler, Panos Roussos, Dan Rujescu, Celso Arango, Alessandro Bertolino, Giuseppe Blasi, Luisella Bocchio-Chiavetto, Dominique Campion, Vaughan Carr, Janice M. Fullerton, Massimo Gennarelli, Javier Gonzalez-Penas, Douglas F. Levinson, Bryan Mowry, Vishwajit L. Nimgaokar, Giulio Pergola, Antonio Rampino, Jorge A. Cervilla, Margarita Rivera, Sibylle G. Schwab, Dieter B. Wildenauer, Mark Daly, Benjamin Neale, Tarjinder Singh, Michael C. O'Donovan, Michael J. Owen, James T. Walters, Muhammad Ayub, Anil K. Malhotra, Todd Lencz, Patrick F. Sullivan, Pamela Sklar, Eli A. Stahl, Laura M. Huckins, Alexander W. Charney, Henry S. Aghanwa, Moin Ansari, Aftab Asif, Rubina Aslam, Jose L. Ayuso, Tim Bigdeli, Stefano Bignotti, Julio Bobes, Bekh Bradley, Peter Buckley, Murray J. Cairns, Stanley V. Catts, Abdul Rashid Chaudhry, David Cohen, Brett L. Collins, Angele Consoli, Javier Costas, Benedicto Crespo-Facorro, Nikolaos P. Daskalakis, Michael Davidson, Kenneth L. Davis, Faith Dickerson, Imtiaz A. Dogar, Elodie Drapeau, Lourdes Fananas, Ayman Fanous, Warda Fatima, Mar Fatjo, Cheryl Filippich, Joseph Friedman, John F. Fullard, Penelope Georgakopoulos, Marianna Giannitelli, Ina Giegling, Melissa J. Green, Olivier Guillin, Blanca Gutierrez, Herlina Y. Handoko, Stella Kim Hansen, Maryam Haroon, Vahram Haroutunian, Frans A. Henskens, Fahad Hussain, Assen V. Jablensky, Jamil Junejo, Brian J. Kelly, Shams-Ud-Din A. Khan, Muhammad N. S. Khan, Anisuzzaman Khan, Hamid R. Khawaja, Bakht Khizar, Steven P. Kleopoulos, James Knowles, Bettina Konte, Agung A. A. A. Kusumawardhani, Naeemullah Leghari, Xudong Liu, Adriana Lori, Carmel M. Loughland, Khalid Mahmood, Saqib Mahmood, Dolores Malaspina, Danish Malik, Amy McNaughton, Patricia T. Michie, Vasiliki Michopolous, Esther Molina, Maria D. Molto, Asim Munir, Gerard Muntane, Farooq Naeem, Derek J. Nancarrow, Amina Nasar, Tanvir Nasr, Jude U. Ohaeri, Jurg Ott, Christos Pantelis, Sathish Periyasamy, Ana G. Pinto, Abigail Powers, Belen Ramos, Nusrat H. Rana, Mark Rapaport, Abraham Reichenberg, Safaa Saker-Delye, Ulrich Schall, Peter R. Schofield, Rodney J. Scott, Megan Shanahan, Cynthia Shannon Weickert, Calvin Sjaarda, Heather J. Smith, Jose Javier Suarez-Rama, Muhammad Tariq, Florence Thibaut, Paul A. Tooney, Muhammad Umar, Elisabet Vilella, Mark Weiser, Jin Qin Wu, Robert Yolken
Summary: A recent study on schizophrenia identified ten genes with a causal role and a concentration of rare variant signals in evolutionarily constrained genes. The study mainly focused on individuals of European ancestry, and the generalizability of the findings in non-European populations is unclear. To address this gap, researchers sequenced a new cohort of schizophrenic cases and controls of diverse ancestries and found consistent results supporting the rare allelic spectrum of the genetic architecture of schizophrenia across different human populations.
Article
Psychology, Clinical
T. Sanchez-Gutierrez, E. Rodriguez-Toscano, L. Roldan, L. Ferraro, M. Parellada, A. Calvo, G. Lopez, M. Rapado-Castro, D. La Barbera, C. La Cascia, G. Tripoli, M. Di Forti, R. M. Murray, D. Quattrone, C. Morgan, J. van Os, P. Garcia-Portilla, S. Al-Halabi, J. Bobes, L. de Haan, M. Bernardo, J. L. Santos, J. Sanjuan, M. Arrojo, A. Ferchiou, A. Szoke, B. P. Rutten, S. Stilo, G. D'Andrea, I. Tarricone, C. M. Diaz-Caneja, C. Arango
Summary: This study analyzed the relationship between tobacco use and first-episode psychosis, age at onset of psychosis, and specific diagnosis of psychosis. The findings showed that patients with first-episode psychosis were more likely to use tobacco and smoke heavily compared to controls. Tobacco use was associated with an earlier age at psychosis onset and a diagnosis of schizophrenia, but these associations were no longer significant after controlling for cannabis use.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Psychology, Clinical
Giulia Trotta, Victoria Rodriguez, Diego Quattrone, Edoardo Spinazzola, Giada Tripoli, Charlotte Gayer-Anderson, Tom P. Freeman, Hannah E. Jongsma, Lucia Sideli, Monica Aas, Simona A. Stilo, Caterina La Cascia, Laura Ferraro, Daniele La Barbera, Antonio Lasalvia, Sarah Tosato, Ilaria Tarricone, Giuseppe D'Andrea, Andrea Tortelli, Franck Schuerhoff, Andrei Szoeke, Baptiste Pignon, Jean-Paul Selten, Eva Velthorst, Lieuwe de Haan, Pierre-Michel Llorca, Paulo Rossi Menezes, Cristina M. Del Ben, Jose Luis Santos, Manuel Arrojo, Julio Bobes, Julio Sanjuan, Miquel Bernardo, Celso Arango, James B. Kirkbride, Peter B. Jones, Alexander Richards, Bart P. Rutten, Jim Van Os, Isabelle Austin-Zimmerman, Zhikun Li, Craig Morgan, Pak C. Sham, Evangelos Vassos, Chloe Wong, Richard Bentall, Helen L. Fisher, Robin M. Murray, Luis Alameda, Marta Di Forti
Summary: This study aims to explore the relationship between childhood adversity and psychosis, and whether cannabis use acts as a mediator between adversity and psychotic disorders. Data from 881 first-episode psychosis patients and 1231 controls were analyzed, and it was found that the association between household discord and psychosis was partially mediated by the use of cannabis. Children exposed to challenging environments could benefit from psychosocial interventions aimed at preventing cannabis misuse.
PSYCHOLOGICAL MEDICINE
(2023)
Review
Microbiology
Emilio Bouza, Celso Arango, Carmen Moreno, Diego Gracia, Manuel Martin, Victor Perez, Luisa Lazaro, Francisco Ferre, Gonzalo Salazar, Francisco Tejerina-Picado, Mercedes Navio, Javier Granda Revilla, Esteban Palomo, Pedro R. Gil-Monte
Summary: The Health Sciences Foundation has conducted research on the impact of the COVID-19 pandemic on mental health, specifically on the general population and healthcare workers. Mental disorders such as anxiety, depression, and sleep disorders have become more prevalent, alongside an increase in suicidal behavior and substance abuse. Vulnerable groups include adolescents and individuals with autism spectrum disorders. Healthcare workers, especially those exposed during the early stages of the pandemic, have experienced higher levels of depression, anxiety, and post-traumatic stress, with factors such as gender, occupation, and previous illnesses playing a role. The media has shown awareness of these issues, highlighting both physical and moral challenges brought on by the crisis.
REVISTA ESPANOLA DE QUIMIOTERAPIA
(2023)
Article
Psychiatry
Lucia Sideli, Monica Aas, Diego Quattrone, Daniele La Barbera, Caterina La Cascia, Laura Ferraro, Luis Alameda, Eva Velthorst, Giulia Trotta, Giada Tripoli, Adriano Schimmenti, Andrea Fontana, Charlotte Gayer-Anderson, Simona Stilo, Fabio Seminerio, Crocettarachele Sartorio, Giovanna Marrazzo, Antonio Lasalvia, Sarah Tosato, Ilaria Tarricone, Domenico Berardi, Giuseppe D'Andrea, Celso Arango, Manuel Arrojo, Miguel Bernardo, Julio Bobes, Julio Sanjuan, Jose Luis Santos, Paulo Rossi Menezes, Cristina Marta Del-Ben, Hannah E. Jongsma, Peter B. Jones, James B. Kirkbride, Pierre-Michel Llorca, Andrea Tortell, Baptiste Pignon, Lieuwe de Haan, Jean-Paul Selten, Jim Van Os, Bart P. Rutten, Richard Bentall, Marta Di Fort, Robin M. Murray, Craig Morgan, Helen L. Fisher
Summary: This study aimed to investigate whether the relationship between childhood maltreatment and cognition in patients with psychosis and community controls was influenced by genetic factors related to psychosis. The study included first-episode psychosis patients (N=755) and unaffected controls (N=1219) from the EU-GEI study, who were assessed for childhood maltreatment, intelligence quotient (IQ), family history of psychosis (FH), and polygenic risk score for schizophrenia (SZ-PRS). The results showed that controlling for FH and SZ-PRS did not weaken the association between childhood maltreatment and IQ in either cases or controls, suggesting that genetic liability factors do not explain the lower levels of cognition in adults who experienced childhood maltreatment.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
(2023)
Article
Psychology, Clinical
Ana Izquierdo, Maria Cabello, Itziar Leal, Iosune Torio, Jose L. M. Madrigal, Karina S. MacDowell, Roberto Rodriguez-Jimenez, David Rentero, Angela Ibanez, Miriam Ayora, Covadonga M. Diaz-Caneja, Renzo Abregii-Crespo, Blanca Mellor-Marsa, Marina Diaz-Marsa, Norberto Malpica, Maria-Fe Bravo-Ortiz, Enrique Baca-Garcia, Celso Arango, Jose Luis Ayuso-Mateos, AGES-CM Grp
Summary: This study aimed to assess whether neighborhood vulnerability and risk of social exclusion could predict functional outcomes in patients with first episode of psychosis. The results showed that patients with first episode of psychosis are more vulnerable to the effects of neighborhood-level characteristics, and higher neighborhood vulnerability is related to greater functional disability in these patients.
JOURNAL OF CLINICAL PSYCHIATRY
(2023)
Article
Psychiatry
Judit Simon, Patrice Boyer, Jose M. Caldas-de-Almeida, Martin Knapp, Paul McCrone, Philip Gorwood, Wolfgang Oertel, Celso Arango, Janet Treasure, Allan H. Young, Frederic Destrebecq, Vinciane Quoidbach
Summary: One in eight individuals worldwide and one in four individuals in many European countries have mental health problems. Three-quarters of mental health disorders develop before age 25, with undiagnosed symptoms often presenting in the mid-teens and lasting into old age. Evidence suggests that people frequently have multiple mental health disorders.
EUROPEAN PSYCHIATRY
(2023)
Article
Psychiatry
Amanda Worker, Pierre Berthert, Andrew J. Lawrence, Seyed Mostafa Kia, Celso Arango, Richard Dinga, Silvana Galderisi, Birte Glenthoj, Rene S. Kahn, Anoushka Leslie, Robin M. Murray, Carmine M. Pariante, Christos Pantelis, Mark Weiser, Inge Winter-van Rossum, Philip Mcguire, Paola Dazzan, Andre F. Marquand
Summary: This study utilized normative modeling of cortical thickness in first-episode psychosis patients to identify individualized cortical markers associated with high biological heterogeneity and deviations in cortical thickness related to the severity of negative symptoms.
TRANSLATIONAL PSYCHIATRY
(2023)
